Page 15 - Dr Reddy’s Laboratories

Poor sales in North America plunge Dr Reddy's Q2 profit; down 60% to Rs 31 cr

Shares of DRL were trading at Rs 3,115.60 on BSE during the morning trading hour, up 0.84 per cent from previous close

Dr Reddy's launches anti-epileptic medicine in the US market

The product is a generic equivalent of Lamictal ODT in the US; Lamictal ODT is a registered trademark of GSK group

Is Dr Reddy's Lab out of the woods?

Faster pace of product launches can drive recovery in growth, but for regulatory clearances

Dr Reddy's to market three more Amgen products in India

The drugs provide treatment options to physicians to address unmet medical needs in the area of oncology and osteoporosis

Dr Reddy's listed on Dow Jones Sustainability Indices 2016

The Dow Jones Sustainability Indices is a leading global benchmark for corporate sustainability

A prescription for success: Dr Reddy's makes pharma packaging more patient-friendly

Redesigns its syrup bottles and blister packs

Dr Reddy's completes acquisition of Teva's US portfolio of 8 products

Pharma major expects some products to add to its topline in 2018; products were being divested by Teva as a condition to close acquisition with Allergan

Company will emerge more stronger and resilient: Dr Reddy's chairman

The company on Tuesday revealed that it was in the process of writing to the USFDA for re-inspection of the three manufacturing sites

Can Dr Reddy's overcome the steep challenges it faces?

Despite assurances, the Indian generics drug major has failed to show any hint of turnaround, however small, from any segment or geography

Dr Reddy's Q1 net down 80% at Rs 126 crore

Pharma major's bottomlines impacted by a decline in volume growth, particularly in the US market and the loss of business in Venezuela

Dr Reddy's Labs Q1 profit slumps 75%

Net profit for the April-June quarter fell to Rs 154 crore from Rs 626 crore the previous year,

Dr Reddy's launches anti-ulcer capsules in US

Drug is generic equivalent of Zegerid capsules, which has a market of $307 million in twelve months to May 2016

Dr Reddy's to have stronger quality system by 2016-end: G V Prasad

This follows firm's remediation efforts after USFDA's warning letter over certain compliance issues last year

Dr Reddy's Lab completes share buyback; stock hit seven-month high

The stock outperformed the market by surging 10% as compared to 0.17% rise in Sensex during past eight trading sessions.

Multiple headwinds for Dr Reddy's in FY17

Price erosion in the US and higher R&D costs are major concerns

Dr Reddy's recalls 50,000 bottles of Ondansetron tabs in US

USFDA says it's a class II recall, initiated when a drug may cause temporary or reversible adverse health conditions

Dr Reddy's profit down 85%

The company saw surge in selling, general and administrative expense surge 7% year-on-year

Dr Reddy's Laboratories announces share buyback offer

The company proposes to spend Rs 1,569.41 crore to buy shares at a maximum price of Rs 3,500 per share

Dr Reddy's, Japan's Eisai ink licensing pact for anti-cancer agent

Eisai will be responsible for the development and marketing of E7777 in Japan and Asia, while Dr Reddy's holds the option for rights to develop and market the agent in India

Dr Reddy's, TR-Pharm ink pact for biosimilar drugs in Turkey

Biosimilar products will be registered and commercialised by T-Pharm